<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Extensive-stage &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/extensive-stage/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 11:44:39 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Extensive-stage &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Hungary&#8217;s Decade of Data Reveals the Harsh Reality of Extensive-Stage Small Cell Lung Cancer</title>
		<link>https://bioengineer.org/hungarys-decade-of-data-reveals-the-harsh-reality-of-extensive-stage-small-cell-lung-cancer/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 11:44:39 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[cell]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Extensive-stage]]></category>
		<category><![CDATA[Hungary]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Real-world evidence]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[small-cell lung cancer]]></category>
		<category><![CDATA[survival outcomes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=426523</guid>

					<description><![CDATA[A nationwide analysis of 8,104 Hungarian patients treated from 2013 to 2022 shows median survival of just 9.3 months with etoposide-platinum chemotherapy, confirming the aggressive nature of extensive-stage small cell lung cancer and setting a national baseline ahead of the immunotherapy era.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">426523</post-id>	</item>
	</channel>
</rss>
